SAN DIEGO, Aug. 26 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical company, announced today the appointment of Mark Spring as Senior Vice President and Chief Financial Officer.
Mr. Spring joins Prometheus with 25 years of experience in finance and accounting. He comes most recently from Hyperion Therapeutics, Inc., where he served as Senior Vice President and Chief Financial Officer. Previously, he was Vice President of Finance and Controller of MedImmune, which was acquired by AstraZeneca for $15 billion in April 2007. Prior to MedImmune, Mr. Spring was Vice President, Finance for Baxter International’s global renal division. Earlier in his career, he held senior finance leadership positions at Dade Behring (now Siemens), Caremark International (now CVS Caremark Corporation) and Fortis, preceded by 12 years in public accounting with Price Waterhouse (now PricewaterhouseCoopers). Mr. Spring earned his bachelor’s degree in business administration from Monmouth College and is a Certified Public Accountant.
“Mark brings a wealth of financial, operational and management experience, which will be very valuable during this important stage of our company’s growth,” said Joseph M. Limber, President and Chief Executive Officer of Prometheus. “He is a welcome addition to our senior management team and will play a key role in planning and executing our core strategy as we continue to build on our success.”
About Prometheus
Prometheus Laboratories Inc. is a specialty pharmaceutical company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is currently focused on the detection, diagnosis and detection of gastrointestinal diseases and disorders in the United States. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus’ corporate offices are located in San Diego, California.
CONTACT: Pete De Spain, Director, Investor Relations & Corporate
Communications of Prometheus Laboratories Inc., +1-858-587-4117,
pdespain@prometheuslabs.com
Web site: http://www.prometheuslabs.com/
